• metastatic/advanced OC (mOC) - 2nd line (L2) 3

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• avelumab based treatment
• avelumab alone
• avelumab plus pegylated liposomal doxorubicin
• Immune checkpoint association
• nivolumab plus ipilimumab

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs anthracyclines
• vs doxorubicin
• vs pegylated liposomal doxorubicin
• vs immune chekpoint inhibitors
• vs anti-PD-(L)1
• vs nivolumab based treatment
• vs nivolumab alone

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  metastatic/advanced OC (mOC) - 2nd line (L2);